Member Company


Poppins (previously Mila) develops digital therapeutics for children with neurodevelopmental disorders. Poppins is designed for early treatment and to increase therapeutic continuity for children with specific learning disorders (SLD). After a successful clinical trial and a €8M financing round, Poppins developed a new therapeutic programme in France opened to all families whose child has a SLD.

Copyright © 2024 Digital Therapeutics Alliance™